Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Net Income (2021 - 2025)

Aligos Therapeutics' Net Income history spans 5 years, with the latest figure at -$19.9 million for Q4 2025.

  • For Q4 2025, Net Income rose 75.8% year-over-year to -$19.9 million; the TTM value through Dec 2025 reached -$24.2 million, up 81.56%, while the annual FY2025 figure was -$24.2 million, 81.56% up from the prior year.
  • Net Income reached -$19.9 million in Q4 2025 per ALGS's latest filing, up from -$31.5 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $43.1 million in Q1 2025 to a low of -$82.1 million in Q4 2024.
  • Average Net Income over 5 years is -$23.4 million, with a median of -$22.4 million recorded in 2022.
  • The largest YoY upside for Net Income was 223.59% in 2025 against a maximum downside of 413.44% in 2025.
  • A 5-year view of Net Income shows it stood at -$37.7 million in 2021, then soared by 41.97% to -$21.9 million in 2022, then fell by 27.44% to -$27.9 million in 2023, then plummeted by 194.53% to -$82.1 million in 2024, then skyrocketed by 75.8% to -$19.9 million in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Net Income are -$19.9 million (Q4 2025), -$31.5 million (Q3 2025), and -$15.9 million (Q2 2025).